验证数据展示
产品信息
10868-1-PBS targets ATP1A3 (C-terminal) in WB, IHC, IF-P, Indirect ELISA applications and shows reactivity with human, mouse, rat samples.
经测试应用 | WB, IHC, IF-P, Indirect ELISA Application Description |
经测试反应性 | human, mouse, rat |
免疫原 | ATP1A3 (C-terminal) fusion protein Ag1313 种属同源性预测 |
宿主/亚型 | Rabbit / IgG |
抗体类别 | Polyclonal |
产品类型 | Antibody |
全称 | ATPase, Na+/K+ transporting, alpha 3 polypeptide |
别名 | |
计算分子量 | 113 kDa |
观测分子量 | 100-113 kDa |
GenBank蛋白编号 | BC015566 |
基因名称 | ATP1A3 |
Gene ID (NCBI) | 478 |
RRID | AB_2060962 |
偶联类型 | Unconjugated |
形式 | Liquid |
纯化方式 | Antigen affinity purification |
UNIPROT ID | P13637 |
储存缓冲液 | PBS only , pH 7.3 |
储存条件 | Store at -80°C. The product is shipped with ice packs. Upon receipt, store it immediately at -80°C |
背景介绍
ATP1A3 participates in the catalyticing hydrolysis of ATP and the exchanging of sodium and potassium ions across plasma membrane. The catalyticing activity mode is ATP + H2O + Na+(In) + K+(Out) = ADP + phosphate + Na+(Out) + K+(In). It has been published that the neurologic disorders rapid-onset dystonia-parkionsonism (RDP), alternating hemiplegia of childhood (ACH) and CAPOS syndrome (cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineural hearing loss) are all related with the mutation of ATP1A3. There are other reports suggest that early life epilepsy and episodic apnea revealing are potentially associated with the mutation of ATP1A3 as a result of impairment of Na+/K+ homeostasis. This antibody is generated against the C-terminal region (665-1013aa) of ATP1A3 and detects the band around 100-113 kDa in SDS-PAGE.(PMID: 30097153, 20301294, 29922587)